

Diagnostic Criteria for Hereditary Non-Polyposis Colorectal Cancer and Microsatellite Instability

Agenda

December 11, 2002

5:00 PM	Arrival/Registration
5:15 PM	Introduction and Divisional Perspectives-I P. Greenwald, Director DCP
5:30 PM	Introduction and Divisional Perspectives-II B.Hiatt, Deputy Director DCCPS
5:45 PM	Plenary talk C.R. Boland
7:00 PM	Dinner

December 12, 2002

8:00 AM	Registration & Breakfast
8:30 AM	Evolution of MSI and Bethesda Guidelines S. Srivastava
8:50 AM	Introduction & Objectives A. Umar/A. Freedman
9:10 AM	Keynote Address and NCI's Perspective J. Carl Barrett, Director CCR
9:30 AM	HNPCC-history and current status H. Lynch
9:50 AM	Microsatellite Instability-Overview and Definitions S. Thibodeau
10:10 AM	-----COFFEE BREAK-----
10:20 AM	Genetic Defects That Lead to MSI phenotype T. Kunkel
10:40 AM	Pathological Manifestations in Clinical Disease S. Hamilton
11:00 AM	ICG and HNPCC/MSI Definitions P. Peltomaki

11:20 AM	MSI and IHC in a large series of carriers of a MMR gene mutation H. Vasen
12:00 PM	MSI in hMLH1 & hMSH2 in sporadic and familial CRC A. Lindbloom
12:20 PM	-----LUNCH-----
1:20 PM	Diagnostic value of immunohistochemistry versus MSI testing in colorectal neoplasia J. Jass
1:40 PM	MSI-H vs MSI-L and carcinogenesis M. Rodriguez-Bigas
2:00 PM	IHC vs NCI panel for MSI A. de la Chapelle
2:20 PM	Comparison of Different Criteria for HNPCC A. Freedman
2:40 PM	Sensitivity and Specificity of the Bethesda Guidelines for the Identification of HNPCC Patients S. Syngal
3:00 PM	Performance characteristics of the Bethesda guidelines: Can the lessons learned from a high-risk registry be applied to the general population? John Terdiman
3:20 PM	-----COFFEE BREAK-----
3:30 -5:30 PM	<p>DISCUSSION</p> <p><i>Discuss, evaluate, and recommend definition of MSI phenotype in cancer; evaluate correlation between MSI phenotype and pathological stages of tumor progression and clinical outcome. Discuss methodological and quality control issues for MSI assays and recommend current guidelines for scoring and reproducibility of these assays. Discuss alternate methods of MSI detection.</i></p> <p>3:30 PM Session I - NCI Panel for MSI Chair/co-chairs: C.R. Boland/ Rodriguez-Bigas Moderator: TBD</p> <p>What are the deficiencies in NCI criteria for MSI detection? Can we effectively assign MSI status of a particular cancer using current guidelines? Is NCI panel of markers sufficient to investigate MSI-H/L? What genetic defects might be associated with MSI+ but no known gene defect?</p>

	<p>Is there a correlation between MSI-H/L and certain gene defects? Refine NCI markers to increase sensitivity and specificity of detection Recommend minimum set of markers that would serve the above mentioned purpose in the context of HNPCC and sporadic MSI cancers Redefine MSI-H and MSI-L based on new data</p> <p>4:10 PM Session II - Immunohistochemistry and alternatives to MSI Chair/co-chairs: J. Jass/ S. Thibodeau Moderator: S. Hamilton</p> <p>New emerging technologies that might help in preclinical and clinical definition of MSI or HNPCC Automated panel vs. conventional gel based MSI analysis Immunohistochemistry; an alternative or substitute for MSI?</p> <p>4:50 PM Session III - Clinical Criteria for HNPCC Classification Chair/co-chairs: C.R. Boland/(S. Syngal) Moderator: (J. Terdiman)</p> <p>Can we define an all inclusive criteria for HNPCC classification Refine Bethesda Criteria to increase sensitivity and specificity for clinical diagnosis</p>
--	--

December 13, 2002

8:00 AM	Registration & Breakfast
9:00 AM	Closing remarks/ Introduction to the final discussion/plans for proceedings <i>A.Freedman/ Asad Umar</i>
9:30 AM	Final thoughts on MSI and carcinogenesis CR Boland
10:00 AM	Recommendations Summary & Discussion -I M. Rodriquez-Bigas
10:30 AM	Recommendations Summary & Discussion -II S. Hamilton
11:00 AM	Recommendations Summary & Discussion -III J. Terdiman
11:30 AM	Adjourn